Intest Res.  2010 Dec;8(2):151-161. 10.5217/ir.2010.8.2.151.

Change of Circulating Leptin, Adiponectin, Resistin, and Visfatin Level after Treatment of Patients with Active Inflammatory Bowel Disease

• Hwangbo Y
• Kim HJ
• Shim J
• Jang JY
• Dong SH
• Kim BH
• Chang YW

• KMID: 2284933
• DOI: http://doi.org/10.5217/ir.2010.8.2.151

Abstract

BACKGROUND/AIMS
The aim of this study was to evaluate the change in circulating levels of adipokines, including leptin, adiponectin, resistin, and visfatin, after induction therapy of patients with active inflammatory bowel disease (IBD).
METHODS
We prospectively evaluated 20 patients with Crohn's disease (CD) and 14 patients with ulcerative colitis (UC) who received induction therapy. The disease activity, body mass index (BMI), and C-reactive protein (CRP) and serum adipolines levels were checked before treatment and 10 weeks after treatment.
RESULTS
After induction therapy, significant reduction of disease activity was noted in patients with CD (CD activity index, 267.9+/-73.7 vs. 50.8+/-36.5, P<0.001) and patients with UC (Mayo score, 9.8+/-2.2 vs. 1.4+/-1.6, P<0.001). The mean serum leptin, adiponectin, resistin, and visfatin levels were 4.0+/-2.7 ng/mL and 4.4+/-2.3 ng/mL (P=0.323), 27.0+/-20.5 microg/mL and 33.8+/-26.5microg/mL (P=0.084), 9.0+/-4.0 ng/mL and 10.2+/-3.2 ng/mL (P=0.108), and 4.6+/-3.7 ng/mL and 2.5+/-4.1 ng/mL (P=0.046) before and after infliximab treatment, respectively. No significant correlation between the changes in BMI, CRP level, or the clinical indices of activity and alterations of the measured adipokines was demonstrated.
CONCLUSIONS
The serum levels of leptin, adiponectin, and resistin showed no significant alterations, whereas the serum visfatin level decreased significantly after induction therapy, suggesting a possible pro-inflammatory property of visfatin and a role as a marker of successful therapy of IBD.

Keyword

Inflammatory Bowel Disease; Leptin; Adiponectin; Resistin; Visfatin

MeSH Terms

Adipokines
Adiponectin
Antibodies, Monoclonal
Body Mass Index
C-Reactive Protein
Colitis, Ulcerative
Crohn Disease
Humans
Infliximab
Inflammatory Bowel Diseases
Leptin
Nicotinamide Phosphoribosyltransferase
Prospective Studies
Resistin
Adipokines
Adiponectin
Antibodies, Monoclonal
C-Reactive Protein
Leptin
Nicotinamide Phosphoribosyltransferase
Resistin